Patents by Inventor Andrew Scharenberg
Andrew Scharenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210222201Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.Type: ApplicationFiled: April 24, 2018Publication date: July 22, 2021Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
-
Publication number: 20210220405Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 11, 2021Publication date: July 22, 2021Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20210147871Abstract: The disclosure relates generally to nucleic acid vectors and packaging cell lines for in vivo expansion of T-cells. More particularly, the disclosure relates to direct intratumoral injection of a lentiviral vector adapted for transduction and drug-mediated expansion of tumor-infiltrating lymphocytes in vivo.Type: ApplicationFiled: April 11, 2019Publication date: May 20, 2021Inventors: Andrew SCHARENBERG, Laurie BEITZ
-
Patent number: 11007224Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: November 16, 2020Date of Patent: May 18, 2021Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Publication number: 20210060080Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: ApplicationFiled: November 16, 2020Publication date: March 4, 2021Inventors: Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
-
Publication number: 20210060079Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: ApplicationFiled: November 16, 2020Publication date: March 4, 2021Inventors: Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI
-
Publication number: 20210000869Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells; expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: ApplicationFiled: March 26, 2019Publication date: January 7, 2021Inventors: Roman Galetto, Julianne SMITH, Andrew SCHARENBERG, Cecile SCHIFFER-MANNIOUI
-
Patent number: 10874693Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: May 12, 2014Date of Patent: December 29, 2020Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Publication number: 20200281979Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: May 17, 2020Publication date: September 10, 2020Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 10563226Abstract: Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.Type: GrantFiled: May 12, 2016Date of Patent: February 18, 2020Assignee: Seattle Children's HospitalInventors: Andrew Scharenberg, David Rawlings, Michael C. Jensen, Kamila Gwiazda, Alexandra Grier
-
Publication number: 20200009266Abstract: In vivo gene therapies for immune deficiencies are described. The in vivo gene therapies utilize a foamy viral vector including a PGK promoter with a therapeutic gene. The foamy viral vector can be beneficially administered with cell mobilization into the peripheral blood.Type: ApplicationFiled: February 15, 2018Publication date: January 9, 2020Applicants: Fred Hutchinson Cancer Research Center, Seattle Children's Hospital d/b/a Seattle Children's Research InstituteInventors: Frieda Chan, Olivier Humbert, Hans-Peter Kiem, Jennifer E. Adair, David Rawlings, Andrew Scharenberg, Troy Torgerson
-
Patent number: 10517896Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: March 22, 2019Date of Patent: December 31, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 10426795Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2013Date of Patent: October 1, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 10378026Abstract: The present invention relates to viral transformation method, particularly foamy virus-mediated transformation method. The present invention relates to the transfer of transgene into cells by the safe and efficient transfer of RNA encoding foamy components. The present invention has therefore therapeutic interest, especially in the field of gene therapy.Type: GrantFiled: September 2, 2014Date of Patent: August 13, 2019Assignee: CELLECTISInventors: Andrew Scharenberg, Julianne Smith, Roman Galetto
-
Patent number: 10363270Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: September 21, 2017Date of Patent: July 30, 2019Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 10357515Abstract: The present invention relates to a method for generating batches of lymphocytes with averaged potency. In particular, the present invention relates to a method of pooling lymphocytes from different donors to avoid NK alloreactivity and anti-HLA immune response. Lymphocytes from each donor are inactivated for at least a gene encoding a TCR component, and are pooled together before be administrated to a subject in need thereof. Thus, this method allows generating batches of lymphocytes with averaged potency, particularly to treat cancer, viral infection or auto-immune disease. The present invention also relates to a batch of lymphocytes obtainable by this method. The batch of lymphocytes can be used to be administrated to one or several patients, being made available as an “off the shelf” therapeutic product, in particular to treat cancer, auto-immune disease or viral infection.Type: GrantFiled: November 21, 2014Date of Patent: July 23, 2019Assignee: CELLECTISInventors: David Sourdive, Carole Desseaux, Andrew Scharenberg
-
Publication number: 20190216853Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20190216854Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20190209616Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells; expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: ApplicationFiled: March 26, 2019Publication date: July 11, 2019Inventors: Roman Galetto, Julianne SMITH, Andrew SCHARENBERG, Cecile SCHIFFER-MANNIOUI
-
Patent number: 10342829Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. 91The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: September 4, 2013Date of Patent: July 9, 2019Assignee: CELLECTISInventors: Julianne Smith, Andrew Scharenberg, Cecile Mannioui, Justin Eyquem